AP2014007797A0 - Glucagon analogues - Google Patents

Glucagon analogues

Info

Publication number: AP2014007797A0
Authority: AP; ARIPO
Prior art keywords: glucagon analogues; glucagon; analogues
Prior art date: 2011-12-23

Application number

AP2014007797A

Other languages

English (en)

Inventor

Ditte Riber

Jakob Lind Tolborg

Dieter Wolfgang Hamprecht

Original Assignee

Boehringer Ingelheim Int

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-23

Filing date

2012-12-19

Publication date

2014-07-31

2012-12-19 Application filed by Boehringer Ingelheim Int, Zealand Pharma As filed Critical Boehringer Ingelheim Int

2014-07-31 Publication of AP2014007797A0 publication Critical patent/AP2014007797A0/xx

Links

MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AP2014007797A 2011-12-23 2012-12-19 Glucagon analogues AP2014007797A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161579888P	2011-12-23	2011-12-23
PCT/EP2012/076137 WO2013092703A2 (en)	2011-12-23	2012-12-19	Glucagon analogues

Publications (1)

Publication Number	Publication Date
AP2014007797A0 true AP2014007797A0 (en)	2014-07-31

Family

ID=47594620

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AP2014007797A AP2014007797A0 (en)	2011-12-23	2012-12-19	Glucagon analogues
AP2014007774A AP2014007774A0 (en)	2011-12-23	2014-07-09	New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AP2014007774A AP2014007774A0 (en)	2011-12-23	2014-07-09	New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them

Country Status (20)

Country	Link
US (2)	US20130316941A1 (xx)
EP (1)	EP2793931A2 (xx)
JP (1)	JP2015502380A (xx)
KR (1)	KR20140114845A (xx)
CN (1)	CN104144696A (xx)
AP (2)	AP2014007797A0 (xx)
AU (1)	AU2012357739A1 (xx)
BR (1)	BR112014015681A2 (xx)
CA (1)	CA2858949A1 (xx)
EA (1)	EA201490982A1 (xx)
HK (1)	HK1200369A1 (xx)
IL (1)	IL232800A0 (xx)
IN (1)	IN2014CN04401A (xx)
MA (1)	MA35864B1 (xx)
MX (1)	MX2014007120A (xx)
PE (1)	PE20142113A1 (xx)
PH (1)	PH12014501336A1 (xx)
SG (1)	SG11201403377QA (xx)
TN (1)	TN2014000224A1 (xx)
WO (1)	WO2013092703A2 (xx)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6054742B2 (ja)	2009-07-13	2016-12-27	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
CA2802897A1 (en)	2010-06-24	2011-12-29	Zealand Pharma A/S	Glucagon analogues
CA2872314C (en)	2012-05-03	2021-08-31	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
EP2664374A1 (en) *	2012-05-15	2013-11-20	F. Hoffmann-La Roche AG	Lysin-glutamic acid dipeptide derivatives
NZ704043A (en)	2012-07-23	2017-07-28	Zealand Pharma As	Glucagon analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en)	2012-12-21	2018-05-28	Sanofi Sa	Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
GB201315335D0 (en) *	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
AR098065A1 (es)	2013-10-17	2016-04-27	Zealand Pharma As	Análogos de glucagón acilados
US9988429B2 (en) *	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
CA2929459C (en)	2013-11-06	2022-05-03	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
AU2014345570B2 (en)	2013-11-06	2019-01-24	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) *	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
EP3212218B1 (en)	2014-10-29	2021-06-30	Zealand Pharma A/S	Gip agonist compounds and methods
AR103242A1 (es) *	2015-01-09	2017-04-26	Lilly Co Eli	Compuestos co-agonistas de gip y glp-1
UA121874C2 (uk)	2015-02-17	2020-08-10	Елі Ліллі Енд Компані	Порошкова назальна композиція для лікування гіпоглікемії
AR103954A1 (es)	2015-03-18	2017-06-14	Zealand Pharma As	Análogos de amilina
WO2016168388A2 (en)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Therapies for obesity, diabetes and related indications
PL3283507T3 (pl) *	2015-04-16	2020-05-18	Zealand Pharma A/S	Acylowany analog glukagonu
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) *	2015-10-26	2018-05-01	美國禮來大藥廠	升糖素受體促效劑
GB2566228A (en)	2016-06-09	2019-03-06	AmideBio LLC	Glucagon analogs and methods of use thereof
AU2017307033B2 (en)	2016-08-05	2020-11-26	Boehringer Ingelheim International Gmbh	Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors
AR109514A1 (es)	2016-09-09	2018-12-19	Zealand Pharma As	Análogos de amilina
KR102502040B1 (ko) *	2016-12-09	2023-02-24	질랜드 파마 에이/에스	아실화 glp-1/glp-2 이중 효능제
ES2973986T3 (es) *	2017-08-16	2024-06-25	Dong A St Co Ltd	Análogo peptídico acilado de oxintomodulina
MX2020008053A (es)	2018-02-02	2020-09-07	Boehringer Ingelheim Int	Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat).
CA3087925A1 (en)	2018-02-02	2019-08-08	Boehringer Ingelheim International Gmbh	Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
JP7225253B2 (ja)	2018-02-02	2023-02-20	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体
CN111655699B (zh)	2018-02-02	2023-07-14	勃林格殷格翰国际有限公司	用作饥饿素o-酰基转移酶(goat)抑制剂的杂环基取代的噁二唑并吡啶衍生物
CN111349155B (zh) *	2018-12-24	2022-04-05	浙江和泽医药科技股份有限公司	一种胰高血糖素类似物及其制备方法和用途
TWI771669B (zh)	2019-04-26	2022-07-21	美商美國禮來大藥廠	製備穩定胜肽調配物之方法
GB201908424D0 (en)	2019-06-12	2019-07-24	Imp College Innovations Ltd	Novel compounds
KR20220100925A (ko)	2019-11-11	2022-07-18	베링거 인겔하임 인터내셔날 게엠베하	Npy2 수용체 작용제
WO2021233884A1 (en)	2020-05-22	2021-11-25	Boehringer Ingelheim International Gmbh	Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
EP4153599B1 (en)	2020-05-22	2024-03-13	Boehringer Ingelheim International GmbH	Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
CN113292646B (zh) *	2020-05-29	2022-05-13	东莞云璟生物技术有限公司	Glp-1/胰高血糖素双重激动剂融合蛋白
WO2022029231A1 (en)	2020-08-07	2022-02-10	Boehringer Ingelheim International Gmbh	Soluble npy2 receptor agonists
IL312600B2 (en)	2022-05-30	2025-12-01	Zealand Pharma As	Liquid formulations of amylin analogs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ295838B6 (cs)	1996-09-09	2005-11-16	Zealand Pharma A/S	Způsob výroby peptidů
AU757658B2 (en)	1998-03-09	2003-02-27	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
EP1891105B1 (en)	2005-06-13	2012-04-11	Imperial Innovations Limited	Oxyntomodulin analogues and their effects on feeding behaviour
EP2471810A1 (en)	2006-02-22	2012-07-04	Merck Sharp & Dohme Corporation	Oxyntomodulin derivatives
ZA200900545B (en)	2006-07-18	2010-03-31	Sanofi Aventis	Antagonist antibody against EPHA2 for the treatment of cancer
NZ578948A (en)	2007-02-15	2012-03-30	Univ Indiana Res & Tech Corp	Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en)	2007-06-15	2008-12-18	Zealand Pharma A/S	Glucagon analogues
TWI541023B (zh)	2008-06-17	2016-07-11	印第安納大學科技研究公司	在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
CA2728284C (en)	2008-06-17	2019-09-10	Richard D. Dimarchi	Glucagon/glp-1 receptor co-agonists
ES2502218T3 (es) *	2008-12-15	2014-10-03	Zealand Pharma A/S	Análogos de glucagón
JP6054742B2 (ja) *	2009-07-13	2016-12-27	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体
WO2011088837A1 (en) *	2010-01-20	2011-07-28	Zealand Pharma A/S	Treatment of cardiac conditions
AR081975A1 (es) *	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon

2012
- 2012-12-19 KR KR1020147020623A patent/KR20140114845A/ko not_active Withdrawn
- 2012-12-19 US US13/720,041 patent/US20130316941A1/en not_active Abandoned
- 2012-12-19 BR BR112014015681A patent/BR112014015681A2/pt not_active IP Right Cessation
- 2012-12-19 SG SG11201403377QA patent/SG11201403377QA/en unknown
- 2012-12-19 HK HK15101109.9A patent/HK1200369A1/xx unknown
- 2012-12-19 JP JP2014547973A patent/JP2015502380A/ja active Pending
- 2012-12-19 EA EA201490982A patent/EA201490982A1/ru unknown
- 2012-12-19 IN IN4401CHN2014 patent/IN2014CN04401A/en unknown
- 2012-12-19 WO PCT/EP2012/076137 patent/WO2013092703A2/en not_active Ceased
- 2012-12-19 AU AU2012357739A patent/AU2012357739A1/en not_active Abandoned
- 2012-12-19 CN CN201280063090.8A patent/CN104144696A/zh active Pending
- 2012-12-19 CA CA2858949A patent/CA2858949A1/en not_active Abandoned
- 2012-12-19 PE PE2014000970A patent/PE20142113A1/es not_active Application Discontinuation
- 2012-12-19 MX MX2014007120A patent/MX2014007120A/es unknown
- 2012-12-19 EP EP12816470.4A patent/EP2793931A2/en not_active Withdrawn
- 2012-12-19 AP AP2014007797A patent/AP2014007797A0/xx unknown
2014
- 2014-05-21 TN TNP2014000224A patent/TN2014000224A1/en unknown
- 2014-05-26 IL IL232800A patent/IL232800A0/en unknown
- 2014-06-11 PH PH12014501336A patent/PH12014501336A1/en unknown
- 2014-07-09 AP AP2014007774A patent/AP2014007774A0/xx unknown
- 2014-07-11 MA MA37205A patent/MA35864B1/fr unknown
2016
- 2016-08-17 US US15/239,154 patent/US20160347813A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PE20142113A1 (es)	2014-12-03
HK1200369A1 (en)	2015-10-09
PH12014501336A1 (en)	2014-09-15
US20130316941A1 (en)	2013-11-28
TN2014000224A1 (en)	2015-09-30
AP2014007774A0 (en)	2014-07-31
MA35864B1 (fr)	2014-12-01
WO2013092703A2 (en)	2013-06-27
EP2793931A2 (en)	2014-10-29
EA201490982A1 (ru)	2015-01-30
IL232800A0 (en)	2014-07-31
JP2015502380A (ja)	2015-01-22
MX2014007120A (es)	2015-03-05
KR20140114845A (ko)	2014-09-29
AU2012357739A1 (en)	2014-07-03
SG11201403377QA (en)	2014-07-30
CA2858949A1 (en)	2013-06-27
BR112014015681A2 (pt)	2019-09-24
WO2013092703A3 (en)	2013-11-14
US20160347813A1 (en)	2016-12-01
IN2014CN04401A (xx)	2015-09-04
CN104144696A (zh)	2014-11-12

Publication	Publication Date	Title
IL232800A0 (en)	2014-07-31	Glucagon analog
ZA201702364B (en)	2019-05-29	Glucagon analogues
IL231199A0 (en)	2014-04-30	New analogs of glucagon
AP3286A (en)	2015-05-31	Glucagon analogues
IL237518A (en)	2017-01-31	Glucagon analog
ZA201306514B (en)	2014-05-28	Novel glucagon analogues
AP2013006671A0 (en)	2013-01-31	Glucagon analogues
ZA201206838B (en)	2013-06-26	Novel glucagon analogues
DK3798230T3 (en)	2022-10-31	Terapeutiske antistoffer
DK2691417T4 (en)	2025-01-02	Antistof fc-varianter
ZA201309626B (en)	2017-09-27	Glucagon/glp-1 reeptor co-agonists
EP2754063A4 (en)	2015-08-05	EXTENSIBILITY OF THE SMB2 PROTOCOL
EP2723631A4 (en)	2015-01-21	QUADFOILER
EP2662268A4 (en)	2014-06-11	CAP MOUNTING STRUCTURE
AP2014007621A0 (en)	2014-05-31	2-Thiopyrimidinones
DK2770906T3 (en)	2021-02-22	Applanationstonometer
ZA201403228B (en)	2017-08-30	Heterocyclypyri(mi)dinylpyrazole
EP2751367A4 (en)	2015-05-06	LADDER
SG11201402471SA (en)	2014-08-28	Photocatalyst-supporting structure
CL2014001638A1 (es)	2014-11-14	Analogos de glucagon
CO7061032A2 (es)	2014-09-19	Análogos de glucagón
AU5171P (en)	2015-11-23	Sunparamiho Mandevilla xamabilis
AU4540P (en)	2013-05-16	BUNNAN Baloskion tetraphyllum
AU5026P (en)	2015-06-03	Goldstrike Agapanthus inapertus
AU5031P (en)	2015-06-04	BESYS Beschorneria yuccoides